Efficacy of a vaccine based on protective antigen and killed spores against experimental inhalational anthrax.

Infection and Immunity
Yves P GauthierDominique R Vidal

Abstract

Protective antigen (PA)-based anthrax vaccines acting on toxins are less effective than live attenuated vaccines, suggesting that additional antigens may contribute to protective immunity. Several reports indicate that capsule or spore-associated antigens may enhance the protection afforded by PA. Addition of formaldehyde-inactivated spores (FIS) to PA (PA-FIS) elicits total protection against cutaneous anthrax. Nevertheless, vaccines that are effective against cutaneous anthrax may not be so against inhalational anthrax. The aim of this work was to optimize immunization with PA-FIS and to assess vaccine efficacy against inhalational anthrax. We assessed the immune response to recombinant anthrax PA from Bacillus anthracis (rPA)-FIS administered by various immunization protocols and the protection provided to mice and guinea pigs infected through the respiratory route with spores of a virulent strain of B. anthracis. Combined subcutaneous plus intranasal immunization of mice yielded a mucosal immunoglobulin G response to rPA that was more than 20 times higher than that in lung mucosal secretions after subcutaneous vaccination. The titers of toxin-neutralizing antibody and antispore antibody were also significantly higher: nine ...Continue Reading

References

Aug 1, 1991·Vaccine·P C Turnbull
Mar 1, 1986·Infection and Immunity·S L WelkosP H Gibbs
May 1, 1986·Infection and Immunity·B E IvinsS H Leppla
Apr 1, 1995·Infection and Immunity·C PezardM Mock
Jan 26, 1996·Journal of Biotechnology·A V StepanovN A Staritsin
Feb 13, 1999·Molecular Microbiology·C Guidi-RontaniM Mock
Sep 4, 1999·Journal of Applied Microbiology·A M Friedlander
Sep 9, 1999·The New England Journal of Medicine·T C DixonP C Hanna
Dec 11, 1999·JAMA : the Journal of the American Medical Association·A M FriedlanderG W Parker
Dec 14, 1999·Microbes and Infection·S F Little, B E Ivins
Mar 18, 2000·Infection and Immunity·F BrossierJ C Sirard
Apr 9, 2001·Clinical Microbiology Reviews·P L OgraR C Welliver
Apr 9, 2001·Infection and Immunity·S ReuvenyB Velan
Dec 12, 2001·Molecular Microbiology·C Guidi-RontaniM Mock
Jan 18, 2002·Infection and Immunity·Fabien BrossierMichèle Mock
Jan 31, 2002·Vaccine·P F FellowsB E Ivins
Jul 9, 2002·Molecular Microbiology·Patricia SylvestreMichèle Mock
Sep 13, 2002·Current Topics in Microbiology and Immunology·A M FriedlanderB E Ivins
Mar 6, 2003·Journal of Bacteriology·Christopher SteichenCharles L Turnbough
May 22, 2003·The Journal of Immunology : Official Journal of the American Association of Immunologists·Prosper N BoyakaJerry R McGhee
Jul 15, 2003·Proceedings of the National Academy of Sciences of the United States of America·Rachel SchneersonJohn B Robbins
Sep 10, 2003·Proceedings of the National Academy of Sciences of the United States of America·Gi-Eun RhieJulia Y Wang
Mar 1, 1956·The Journal of Hygiene·D W HENDERSONF C BELTON

❮ Previous
Next ❯

Citations

Aug 26, 2009·Infection and Immunity·Cassandra D Kelly-Cirino, Nicholas J Mantis
Sep 23, 2009·Expert Opinion on Biological Therapy·Dennis M KlinmanKoji Tomaru
Jun 18, 2010·Trends in Molecular Medicine·Jean-Nicolas Tournier, Mansour Mohamadzadeh
Oct 20, 2009·Vaccine·Shan Lu, Shixia Wang
Aug 18, 2009·Molecular Aspects of Medicine·Adam Driks
Sep 5, 2009·Molecular Aspects of Medicine·Robert J CybulskiAlison D O'Brien
Jun 7, 2011·The American Journal of Pathology·Fabien DumetzPierre Louis Goossens
Apr 18, 2012·Biochemical and Biophysical Research Communications·Makoto UchidaKeiko Kawamoto
Apr 2, 2015·PLoS Neglected Tropical Diseases·Christophe BrézillonPierre L Goossens
Jul 1, 2009·Molecular Aspects of Medicine·R John Collier
Oct 30, 2015·Microbiology and Molecular Biology Reviews : MMBR·George C Stewart
Sep 21, 2016·Infection and Immunity·Miriam A BalderasAnthony W Maresso
Jul 2, 2016·Applied Microbiology and Biotechnology·Nagendra SuryanarayanaVanlal Hmuaka
Jul 28, 2020·Frontiers in Immunology·Dina R WeilhammerAmy Rasley
Jan 28, 2010·Journal of Medicinal Chemistry·Dimitrios G Bouzianas
Jun 25, 2015·Microbiology Spectrum·Susan WelkosChristopher Cote
Nov 7, 2015·Microbiology Spectrum·Joel A BozueChristopher K Cote

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anthrax Vaccines

Three different types of anthrax vaccines are available; a live-attenuated, an alum-precipitated cell-free filtrate and a protein recombinant vaccine. The effectiveness between the three is uncertain, but the live-attenuated have shown to reduce the risk of anthrax with low adverse events. Here is the latest research on anthrax vaccines.

Anthrax Vaccines (ASM)

Three different types of anthrax vaccines are available; a live-attenuated, an alum-precipitated cell-free filtrate and a protein recombinant vaccine. The effectiveness between the three is uncertain, but the live-attenuated have shown to reduce the risk of anthrax with low adverse events. Here is the latest research on anthrax vaccines.

Anthrax

Anthrax toxin, comprising protective antigen, lethal factor, and oedema factor, is the major virulence factor of Bacillus anthracis, an agent that causes high mortality in humans and animals. Here is the latest research on Anthrax.